NCT00880360View on ClinicalTrials.gov

A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
Epithelial Ovarian CancerExtraovarian Peritoneal CancerFallopian Tube Carcinoma
Interventions
DRUG

Ontak

Patients will be treated with Ontak at 12 µg/kg monthly as long as they meet response criteria.

Trial Locations (1)

78229

CTRC at UTHSCSA, San Antonio

All Listed Sponsors
lead

The University of Texas Health Science Center at San Antonio

OTHER

NCT00880360 - A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer | Biotech Hunter | Biotech Hunter